<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110071</url>
  </required_header>
  <id_info>
    <org_study_id>1943.00</org_study_id>
    <secondary_id>NCI-2009-01470</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <nct_id>NCT00110071</nct_id>
  </id_info>
  <brief_title>Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Clinical Trial Evaluating I131-Tositumomab (Anti-CD20) With Escalating Doses of Fludarabine Followed by Autologous or Syngeneic Stem Cell Transplantation for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma in Patients 60 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of fludarabine (fludarabine&#xD;
      phosphate) when given together with iodine I 131 tositumomab in treating older patients who&#xD;
      are undergoing an autologous or syngeneic stem cell transplant for relapsed or refractory&#xD;
      B-cell non-Hodgkin's lymphoma (NHL). Radiolabeled monoclonal antibodies, such as iodine I 131&#xD;
      tositumomab, can find cancer cells and carry cancer-killing substances to them without&#xD;
      harming normal cells. Drugs used in chemotherapy, such as fludarabine, work in different ways&#xD;
      to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that&#xD;
      were destroyed by chemotherapy and radiation therapy. Giving iodine I 131 tositumomab&#xD;
      together with fludarabine followed by autologous stem cell transplant may be an effective&#xD;
      treatment for NHL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximally tolerated dose of fludarabine that can be combined with&#xD;
      131I-anti-CD20 (iodine I 131 tositumomab) delivering =&lt; 27Gy to critical normal organs&#xD;
      followed by autologous or syngeneic transplantation in patients &gt;= 60 years of age with&#xD;
      relapsed B-NHL.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the overall and progression-free survival of the above regimen in such patients.&#xD;
&#xD;
      II. To evaluate the response rates of the above therapy.&#xD;
&#xD;
      III. To evaluate the toxicity and tolerability of the above therapy.&#xD;
&#xD;
      IV. To evaluate the feasibility of delivering concurrent high-dose radioimmunotherapy (RIT)&#xD;
      and chemotherapy.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of fludarabine phosphate as used in combination with&#xD;
      I 131 tositumomab and stem cell transplant.&#xD;
&#xD;
      Patients receive a dosimetric dose of iodine I 131 tositumomab intravenously (IV) over 40-60&#xD;
      minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then&#xD;
      receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on&#xD;
      day -14. Patients also receive fludarabine phosphate IV once daily (QD) on days -11 to -9 OR&#xD;
      days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell&#xD;
      transplantation on day 0.&#xD;
&#xD;
      Patients with circulating lymphoma cells by peripheral smear receive tositumomab IV over 1&#xD;
      hour OR rituximab IV over 1 hour followed by tositumomab IV over 1 hour before the dosimetric&#xD;
      iodine I 131 tositumomab infusion.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months and&#xD;
      then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose/dose limiting toxicity</measure>
    <time_frame>Up to 30 days post-transplant</time_frame>
    <description>Assessed according to Bearman scale for Regimen-Related Toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall and progression-free survival rate</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity/tolerability of study regimen</measure>
    <time_frame>Through day 100 post-transplant</time_frame>
    <description>Type, frequency, and severity of adverse events grade 3 and above (assessed by National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of concurrent high-dose radioimmunotherapy and chemotherapy</measure>
    <time_frame>Through day -7 prior to transplant</time_frame>
    <description>Ability to administer complete course of I 131-tositumomab and fludarabine phosphate as descried in protocol.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (chemoradioimmunotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a dosimetric dose of iodine I 131 tositumomab IV over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV QD on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemoradioimmunotherapy)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)</description>
    <arm_group_label>Treatment (chemoradioimmunotherapy)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 tositumomab</intervention_name>
    <description>Given IV (dosimetric dose) or via central line (therapeutic dose)</description>
    <arm_group_label>Treatment (chemoradioimmunotherapy)</arm_group_label>
    <other_name>131-I-anti-B1 antibody</other_name>
    <other_name>131-I-anti-B1 monoclonal antibody</other_name>
    <other_name>I131-MOAB-B1</other_name>
    <other_name>iodine I 131 MOAB anti-B1</other_name>
    <other_name>iodine I 131 monoclonal antibody anti-B1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemoradioimmunotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemoradioimmunotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemoradioimmunotherapy)</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a histologically confirmed diagnosis of lymphoma expressing the&#xD;
             CD20 antigen and generally must have failed at least one prior standard systemic&#xD;
             therapy; the exception will be mantle cell lymphoma (MCL) patients, who may be&#xD;
             enrolled while in first complete remission (CR) in accordance with current transplant&#xD;
             standard of care for these patients&#xD;
&#xD;
          -  Creatinine (Cr) &lt; 2.0&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL, with the exception of patients thought to have Gilbert's&#xD;
             syndrome, whom may have a total bilirubin above 1.5 mg/dL&#xD;
&#xD;
          -  All patients eligible for therapeutic study must have (&gt;= 2x10^6 CD34/kg) autologous&#xD;
             hematopoietic stem cells harvested and cryopreserved, or this number of cells&#xD;
             harvested from a syngeneic donor&#xD;
&#xD;
          -  Patients must have an expected survival of &gt; 60 days and must be free of major&#xD;
             infection&#xD;
&#xD;
          -  DONOR: Syngeneic donors must be confirmed syngeneic by ABO typing, human leukocyte&#xD;
             antigen (HLA) typing, and variable number tandem repeat (VNTR) analysis&#xD;
&#xD;
          -  DONOR: Syngeneic donors must meet eligibility under Standard Practice&#xD;
             Guidelines/Standard Treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Circulating anti-mouse antibody (HAMA) (to be determined before both dosimetry and&#xD;
             therapy)&#xD;
&#xD;
          -  Systemic anti-lymphoma therapy given in the previous 30 days before the scheduled&#xD;
             therapy dose&#xD;
&#xD;
          -  Inability to understand or give an informed consent&#xD;
&#xD;
          -  Prior radiation &gt; 20 Gy to any critical normal organ (e.g., lung, liver, spinal cord,&#xD;
             &gt; 25% of red marrow)&#xD;
&#xD;
          -  Central nervous system lymphoma&#xD;
&#xD;
          -  Other serious medical conditions considered to represent contraindications to bone&#xD;
             marrow transplant (BMT) (e.g., abnormally decreased cardiac ejection fraction,&#xD;
             diffusing capacity (DLCO) &lt; 50% predicted, patient on supplemental oxygen, acquired&#xD;
             Immunodeficiency syndrome [AIDS], etc.)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prior bone marrow or stem cell transplant&#xD;
&#xD;
          -  South West Oncology Group (SWOG) performance status &gt;= 2&#xD;
&#xD;
          -  Unable to perform self-care during radiation isolation&#xD;
&#xD;
          -  Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma/well&#xD;
             differentiated lymphocytic lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Gopal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tositumomab I-131</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

